Core Insights - Altamira Therapeutics has successfully launched Bentrio in Norway and has extended its exclusive distribution agreement with Pharma Nordic AS to include Sweden and Denmark, aiming to introduce the product in these markets next year [1][2] Company Overview - Altamira Therapeutics is focused on developing peptide-based nanoparticle technologies for RNA delivery, with two flagship siRNA programs in preclinical development targeting KRAS-driven cancer and rheumatoid arthritis [4] - The company holds a 49% stake in Altamira Medica AG, which commercializes Bentrio, an OTC nasal spray for allergic rhinitis [4] Product Details - Bentrio is a drug-free nasal spray designed to protect against airborne allergens and viruses, forming a protective gel layer in the nasal mucosa [3] - Clinical trials, including the NASAR study with 100 participants, demonstrated Bentrio's efficacy in reducing nasal symptoms and improving quality of life compared to saline [3] Market Expansion - The positive reception of Bentrio in Norway has prompted plans for its introduction in Sweden and Denmark, where there is a shared interest in innovative healthcare products [2][3]

Core Insights - Altamira Medica Ltd. announced that its Bentrio® nasal spray has been independently tested and found free of over 230 prohibited substances listed by the World Anti-Doping Agency (WADA), confirming its suitability for athletes [1][3] - The nasal spray is designed to protect against airborne allergens and particles while complying with anti-doping regulations, addressing the challenges athletes face in managing allergic rhinitis [2][3] Company Overview - Altamira Therapeutics Ltd. is focused on developing peptide-based nanoparticle technologies for RNA delivery, with two flagship siRNA programs in preclinical development targeting KRAS-driven cancer and rheumatoid arthritis [5][6] - The company holds a 49% stake in Altamira Medica AG, which commercializes Bentrio®, an over-the-counter nasal spray for allergic rhinitis [6] Product Details - Bentrio® is a drug-free and preservative-free nasal spray that forms a protective gel layer on the nasal mucosa, preventing airborne particles from contacting cells and aiding in their discharge [4] - Clinical trials, including the NASAR study with 100 participants, demonstrated Bentrio's efficacy in reducing allergy symptoms and improving quality of life, with statistically significant results [4]

Hamilton, Bermuda, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Treatment with ZbtbB46 mRNA nanoparticles based on Altamira's SemaPhore™ delivery technology results in significant reduction in tumor growth (p<0.0001) Combination of nanoparticles with immune checkpoint inhibitor (anti-PD1) shows even more pronounced improvement, synergistic control of tumor growth with long-term complete remission of tumor in many cases Combination therapy may help to render more solid tumor patients responsive to anti-PD1 therapies (i ...

Study shows significant reduction in aorta dilation, delayed rupture and lower mortality in established animal model of abdominal aortic aneurysm Altamira's SemaPhore™ nanoparticles delivering SOD2 mRNA successfully to mitochondria in aorta wall Positive outcomes suggest potential use of treatment in management of small abdominal aortic aneurysm and prevention of ruptures AAA is a localized abnormal enlargement (bulge) of the abdominal aorta, i.e. the part of the main artery which runs through the belly. Th ...

Study shows significant reduction in aorta dilation, delayed rupture and lower mortality in established animal model of abdominal aortic aneurysm Altamira's SemaPhore™ nanoparticles delivering SOD2 mRNA successfully to mitochondria in aorta wall Positive outcomes suggest potential use of treatment in management of small abdominal aortic aneurysm and prevention of ruptures "Using SOD2 mRNA to modulate oxidative stress appears a very promising approach in various challenging cardiovascular disorders such as a ...

Hamilton, Bermuda, June 20, 2024 (GLOBE NEWSWIRE) -- BPPV is characterized by repeated episodes of vertigo produced by changes in the head position relative to gravity, e.g. when tipping the head backward. It is typically caused by dislodged inner ear particles (otoconia) in one of the semicircular canals, most often the posterior canal. The debris elicits unwanted vestibular stimulation and is often cleared through physical repositioning procedures such as the Epley maneuver, which is strongly recommended ...

Even in case of a successful physical repositioning procedure, patients may experience residual dizziness. This may last for a few days up to several weeks and may affect quality of life and be of incapacitating nature. Residual dizziness may be due to, among others, remaining otoconia, incomplete vestibular compensation or microcirculation dysfunction. Based on their review of available treatment options, the authors of the publication suggest the use of vestibular habituation therapies and vestibular reha ...

Hamilton, Bermuda, May 28, 2024 (GLOBE NEWSWIRE) -- Achieved significant improvement in handling and transport stability of RNA nanoparticles Pursuing partnering opportunities with AM-125 legacy asset in vertigo and / or potential other CNS indications Streamlining corporate structure; switch in financial reporting from Swiss Francs to US Dollars HAMILTON, BERMUDA / May 28, 2024 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing and commercializing RN ...

Hamilton, Bermuda, May 28, 2024 (GLOBE NEWSWIRE) -- Achieved significant improvement in handling and transport stability of RNA nanoparticles Pursuing partnering opportunities with AM-125 legacy asset in vertigo and / or potential other CNS indications Streamlining corporate structure; switch in financial reporting from Swiss Francs to US Dollars HAMILTON, BERMUDA / May 28, 2024 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing and commercializing RN ...

Hamilton, Bermuda, May 23, 2024 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA – May 23, 2024 - - Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that highlights from the NASAR clinical trial with Bentrio® nasal spray in seasonal allergic rhinitis (SAR) have been published in video format on the social media channels of Allergy, one of the highest-ranking journals in the ...